Shanghai Henlius Biotech

2696 · HKEX

Public Market Listing

2696HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Henlius Biotech are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(14 total)
14Total Assets
0Approved
6Phase 3 / Filed
8Phase 1–2 / Early
8Diseases
Quick filter:
Showing 14 of 14 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
HLX01(Hanlikang)No recent activity
Phase 3
CD20Monoclonal antibody
Rheumatoid Arthritis
HLX04(Hanbeitai)
Phase 3
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer
Phase 2/3
PD-L1Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2/3
EGFRMonoclonal antibody
Non-Small Cell Lung Cancer
Phase 2
BRAF V600ESmall molecule
Non-Small Cell Lung Cancer
Phase 2
LAG-3Monoclonal antibody
Non-Small Cell Lung Cancer
HLX208 + HLX10No recent activity
Phase 1/2
BRAF V600E + PD-1 (combination regimen)Combination
Non-Small Cell Lung Cancer
HLX301No recent activity
Phase 1/2
PD-L1 / TIGITMultispecific antibody
Non-Small Cell Lung Cancer
HLX35No recent activity
Phase 1
EGFR x 4-1BB (CD137)Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1
EGFRAntibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
HLX43Phase 2Nasopharyngeal Carcinoma (NPC)
Est. primary completion 2026-11-22 · NCT06839066 · CT.gov ↗
What to watch
December 2026 (3)
HLX43Phase 2Hormone Receptor Positive HER-2 Negative Breast Cancer
Est. primary completion 2026-12-30 · NCT07459738 · CT.gov ↗
What to watch
HLX43Phase 2Colorectal Cancer (CRC)
Est. primary completion 2026-12-30 · NCT07106892 · CT.gov ↗
What to watch
HLX43Phase 2Cervical Cancer, Ovarian Cancer
Est. primary completion 2026-12-31 · NCT06769152 · CT.gov ↗
What to watch
2027 (6)
May 2027 (1)
HLX43 + SerplulimabPhase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
June 2027 (1)
HLX43 + SerplulimabPhase 2Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
July 2027 (2)
HLX15Phase 3Newly Diagnosed Multiple Myeloma
Est. primary completion 2027-07 · NCT06895512 · CT.gov ↗
What to watch
Pimurutamab + HLX43 + SerplulimabPhase 1/2Colon Cancer Adenocarcinoma
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
August 2027 (1)
HLX43Phase 2Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-08-30 · NCT07115485 · CT.gov ↗
What to watch
December 2027 (1)
Pimurutamab + HLX43 + SerplulimabPhase 2Carcinoma of Head and/or Neck
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
HLX43Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2028-02-21 · NCT07301229 · CT.gov ↗
What to watch
April 2028 (1)
HLX43Phase 2Non Small Cell Lung Cancer
Est. primary completion 2028-04-20 · NCT06907615 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Pimurutamab + HLX43Phase 2/3Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Est. primary completion 2030-01-15 · NCT07459751 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Pimurutamab + SerplulimabPhase 2/3Squamous NSCLC
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 June 2026Topline resultHLX04-OInternational Phase 3 of HLX04-O vs ranibizumab (NCT04740671) met its primary endpoint
Henlius · Source ↗
February 2026Filing acceptedFHND9041NMPA accepted the FHND9041 NDA for first-line EGFR 19del NSCLC
CN, NMPA · Source ↗
13 August 2025Filing acceptedHLX04-ONMPA CDE accepts the NDA for HLX04-O (ophthalmic bevacizumab) in wet AMD
CN, NMPA · Shanghai Henlius Biotech · Source ↗
2 April 2025Topline resultHLX04-OChina Phase 3 of HLX04-O vs ranibizumab (NCT05003245) met its primary endpoint
Henlius · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$928M$347M——report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$797M$256M——report ↗